- Advertise
- About OncLive
- Editorial Board
- MJH Life Sciences brands
- Contact Us
- Privacy
- Terms & Conditions
- Do Not Sell My Information
2 Clarke Drive
Suite 100
Cranbury, NJ 08512
© 2024 MJH Life Sciences™ and OncLive - Clinical Oncology News, Cancer Expert Insights. All rights reserved.
Moffitt Cancer Center | Strategic Alliance Partners
Moffitt is dedicated to one lifesaving mission: to contribute to the prevention and cure of cancer. The Tampa-based facility is one of only 53 National Cancer Institute-designated Comprehensive Cancer Centers, a distinction that recognizes Moffitt’s scientific excellence, multidisciplinary research, and robust training and education. Moffitt’s expert nursing staff is recognized by the American Nurses Credentialing Center with Magnet® status, its highest distinction. With more than 7,800 team members, Moffitt has an economic impact in the state of $2.4 billion. For more information, call 1-888-MOFFITT (1-888-663-3488), visit MOFFITT.org, and follow the momentum on Facebook, Twitter, Instagram and YouTube.
Latest from Moffitt Cancer Center
Dr Forsyth on a Phase 1 Study Evaluating Intrathecal cDC1s in Leptomeningeal Disease
November 20, 2024
Video
Peter Forsyth, MD, discusses the design of a first-in-human phase 1 trial evaluating HER2/HER3–targeted intrathecal dendritic cells in leptomeningeal disease.
Dr Kim on the CARES-310 Study of Rivoceranib Plus Camrelizumab in First-Line HCC
November 19, 2024
Video
Richard Kim, MD, discusses the phase 3 CARES-310 trial evaluating rivoceranib plus camrelizumab in first-line hepatocellular carcinoma.
Dr Biachi on the Evolving Role for Surgery in CRC
November 12, 2024
Video
Tiago Biachi, MD, PhD, discusses the evolving role for surgery in colorectal cancer.
Dr Lotan on Factors Informing Treatment Selection in BCG-Unresponsive NMIBC
October 28, 2024
Video
Yair Lotan, MD, discusses factors informing treatment selection for patients with BCG-unresponsive non-muscle invasive bladder cancer.
utDNA Could Provide Noninvasive Tool for MRD Detection Prior to Repeat TURBT in High-Risk NMIBC
September 13, 2024
Article
Joshua Linscott, MD, PhD, discusses the use of urinary cell-free tumor DNA for MRD detection prior to repeat resection in high-risk NMIBC.
Dr Kim on the Safety of NT-17 Plus Pembrolizumab in Pretreated CRC and PDAC
September 11, 2024
Video
Richard Kim, MD, discusses the safety of NT-17 and next steps for its evaluation in pretreated microsatellite stable CRC and PDAC.
Dr Linscott on the Use of Urinary Cell-free Tumor DNA to Predict MRD in High-Risk NMIBC
September 10, 2024
Video
Joshua Linscott, MD, PhD, discusses the use of utDNA to predict MRD prior to repeat TURBT in patients with high-risk non-muscle invasive bladder cancer.
Zanubrutinib Associated With Lower Switching Rates vs Other Covalent BTK Inhibitors in CLL/SLL
September 09, 2024
Article
Zanubrutinib was associated with lower treatment switching rates vs acalabrutinib and ibrutinib in real-world chronic lymphocytic leukemia.
Dr Li on Safety Data Derived From the CORE-001 Trial in BCG-Unresponsive NMIBC
August 30, 2024
Video
Roger Li, MD, discusses safety data from the final analysis of the CORE-001 trial in BCG-unresponsive non–muscle-invasive bladder cancer.
Dr Li on Cretostimogene Grenadenorepvec Plus Pembrolizumab in BCG-Unresponsive NMIBC
August 29, 2024
Video
Roger Li, MD, discusses the final analysis of the CORE-001 trial of cretostimogene grenadenorepvec plus pembrolizumab in BCG-unresponsive NMIBC with CIS.
Dr Forsyth on the Potential Utility of Intrathecal cDC1s in Leptomeningeal Disease
August 27, 2024
Video
Peter Forsyth, MD, discusses the evaluation of intrathecal dendritic cells for patients with TNBC/HER2-positive leptomeningeal disease.
Dr Linscott on the Need for Improved MRD Detection in High-Risk NMIBC
August 23, 2024
Video
Joshua Linscott, MD, PhD, discusses a study evaluating a utDNA assay for minimal residual disease detection in patients with high-risk NMIBC.
Dr Li on the Clinical Implications of a Post Hoc Analysis of KEYNOTE-057 in BCG-Unresponsive NMIBC
August 22, 2024
Video
Roger Li, MD, discusses the implications of a post hoc analysis of the KEYNOTE-057 trial in BCG-unresponsive, high-risk non–muscle-invasive bladder cancer.
Dr Tarhini on the Combination of High-Dose Bolus IL-2 and CTLA-4 Inhibition in Advanced Melanoma
August 19, 2024
Video
Ahmad Tarhini, MD, PhD, discusses the hypothesis for investigating high-dose bolus IL-2 plus an anti–CTLA-4 agent in patients with advanced melanoma.
Dr Tarhini on Hogh-Dose Bolus IL-2 With Ipilimumab Followed by Nivolumab in Melanoma
August 16, 2024
Video
Ahmad Tarhini, MD, PhD, discusses the use of high-dose bolus IL-2 with ipilimumab followed by nivolumab in advanced melanoma following prior progression.
Dr Kim on Current Unmet Needs in the Management of Resectable CRC
August 16, 2024
Video
Richard Kim, MD, discusses the current treatment paradigm for patients with resectable CRC, as well as unmet needs in this population.
Dr Li on the Rationale for a Post Hoc Analysis of KEYNOTE-057 in BCG-Unresponsive NMIBC
August 13, 2024
Video
Roger Li, MD, details a post hoc analysis of patients with BCG-unresponsive non–muscle-invasive bladder cancer who did not respond to pembrolizumab.
Dr Linscott on Future Directions for utDNA Research in Bladder Cancer
August 08, 2024
Video
Joshua Linscott, MD, PhD, discusses a study investigating the use of utDNA to predict MRD prior to rTURBT in NMIBC.
Bladder-Sparing Treatment Post–Pembrolizumab Progression Is Effective in BCG-Unresponsive NMIBC
August 02, 2024
Article
Roger Li, MD, discusses the efficacy of bladder-sparing therapy after progression on pembrolizumab in patients with BCG-unresponsive, high-risk NMIBC.
Exploring Unmet Needs to Optimize Neoadjuvant Therapy in Resectable CRC
July 19, 2024
Article
Richard Kim, MD, discusses the standard treatment approaches and unmet needs for patients with resectable colorectal cancer.